| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
The Institute for Cancer Research, The Fox Chase Cancer Center, Philadelphia 19111 [H. L. H., H. M. L.], and Children's Hospital of Philadelphia, Philadelphia 19104 [H. L. H., A. E. E.], Pennsylvania
Elevated serum ferritin levels without a corresponding increase in tissue iron storage have been observed in patients with certain cancers. Increased synthesis of ferritin by cancer cells has also been reported. In order to see whether similar phenomena occurred in patients with neuroblastoma, we have screened serum ferritin levels in 58 children with neuroblastoma by counterelectrophoresis using antibody to human ferritin. Increased ferritin levels in serum, positive by counterelectrophoresis (
400 ng/ml), correlated well with the presence of active disease (p < 0.001 by Fisher's exact 2 x 2 test). A longitudinal study of serum ferritin levels in 34 of the 58 patients showed the same association of elevated serum ferritin with active disease; a return of ferritin levels to the normal ranges coincided with remission. Primary neuroblastoma tumors and cells from neuroblastoma cell lines contained ferritins with the electrophoretic characteristics different from normal liver ferritin. Supernatant fluids from six neuroblastoma cell lines grown in culture also contained ferritin. These findings suggest that the increased ferritin in the serum of patients is derived from the tumor. The serum ferritin level could be used as indicator of disease activity and as a guide to therapy.
1 This work was supported by USPHS Grants CA-06551, RR-05539, CA-06927, CA-14489, and CA-13451 from the NIH; by an appropriation from the Commonwealth of Pennsylvania; and by the Elaine O. Weiner Foundation Trust.
2 To whom requests for reprints should be addressed, at the Institute for Cancer Research, The Fox Chase Cancer Center, Philadelphia, Pa. 19111.
Received 8/20/79. Accepted 1/25/80.
This article has been cited by other articles:
|
|
 |
|
  M.-D. Leclair, O. Hartmann, Y. Heloury, L. Fourcade, A. Laprie, F. Mechinaud, C. Munzer, and H. Rubie Localized Pelvic Neuroblastoma: Excellent Survival and Low Morbidity With Tailored Therapy--The 10-Year Experience of the French Society of Pediatric Oncology J. Clin. Oncol., May 1, 2004; 22(9): 1689 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Weinstein, H. M. Katzenstein, and S. L. Cohn Advances in the Diagnosis and Treatment of Neuroblastoma Oncologist, June 1, 2003; 8(3): 278 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Gray, P. Arosio, and P. Hersey Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells Blood, May 1, 2002; 99(9): 3326 - 3334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Raggi, M. Maggi, D. Renzi, A. Calabrò, M. L. Bagnoni, P. Scaruffi, G. P. Tonini, M. Pazzagli, B. De Bernardi, G. Bernini, et al. Quantitative Determination of sst2 Gene Expression in Neuroblastoma Tumor Predicts Patient Outcome J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3866 - 3873. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. C. Raggi, M. L. Bagnoni, G. P. Tonini, M. Maggi, G. Vona, P. Pinzani, K. Mazzocco, B. De Bernardi, M. Pazzagli, and C. Orlando Real-Time Quantitative PCR for the Measurement of MYCN Amplification in Human Neuroblastoma with the TaqMan Detection System Clin. Chem., November 1, 1999; 45(11): 1918 - 1924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Cohn Neuroblastoma Update: Prognostic Factors Journal of Pediatric Oncology Nursing, January 1, 1988; 5(1-2): 28 - 29. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
